What type of study is this?

This is a Systematic Review study (also classified as: Meta-Analysis).

September 10, 2025Open Access

Efficacy and Safety of Tapinarof for Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Key Points

Tapinarof 1% significantly improved IGA success rates after eight weeks, indicating better treatment outcomes.
Patients showed higher EASI-75 response rates with tapinarof compared to placebo, supporting its efficacy in AD.
The study followed PRISMA guidelines and included data from four randomized controlled trials involving 1191 patients.
While tapinarof led to a modest increase in adverse events, serious AEs were not significantly different between groups.

Abstract

This systematic review and meta-analysis evaluated the efficacy and safety of 1% tapinarof cream once daily (QD) in patients with mild-to-severe atopic dermatitis (AD). Adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched PubMed, Embase, Cochrane, and ClinicalTrials.gov databases for placebo-controlled, randomized trials up to March 2025. Four studies reporting five randomized trials involving a total of 1191 patients met the inclusion criteria. Primary endpoints included Investigator Global Assessment (IGA) success and achievement of Eczema Area and Severity Index 75% (EASI-75) response. Secondary outcomes included improvement in Peak Pruritus Numeric Rating Scale (PP-NRS) scores and incidence of adverse events (AEs). After eight weeks, patients receiving tapinarof 1% QD were associated with significantly higher IGA success rates (risk ratio (RR) = 3.03, 95% CI: 1.94-4.74, p = 0.002), EASI-75 response rates (RR = 2.99, 95% CI: 1.94-4.60, p = 0.002), and clinically meaningful improvement in PP-NRS scores of ≥4 points (RR = 1.58, 95% CI: 1.10-2.26, p = 0.03) compared to placebo. Tapinarof also showed a modest but statistically significant increase in the overall incidence of adverse events (AEs) (RR = 1.39, 95% CI: 1.02-1.90, p = 0.04), while the rate of serious AEs was not significantly different between groups (RR = 1.98, 95% CI: 0.36-24.69, p = 0.31). In conclusion, tapinarof cream 1% QD demonstrated significant efficacy in treating mild-to-severe AD, with improvements in clinical signs and pruritus. It was generally well tolerated, supporting its use as a non-steroidal topical therapy in this patient population. Protocol registered in International Prospective Register of Systematic Reviews (PROSPERO) (CRD420251000807), with risk of bias assessed using the Cochrane risk-of-bias (RoB 2) tool and certainty of evidence appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Saifi et al. (Wed,) studied this question.

synapsesocial.com/papers/68c188509b7b07f3a0612139 https://doi.org/https://doi.org/10.7759/cureus.91549

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper